Skip to main content
logo
Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
127.70
-0.87 (-0.68%)
Jul 9, 2026, 4:00 PM EDT - Market closed

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Livmarli Revenue
400.59M360.01M213.30M
Livmarli Revenue Growth
11.27%68.78%50.42%
Bile Acid Medicines Revenue
169.02M161.31M123.11M
Bile Acid Medicines Revenue Growth
4.78%31.02%232.03%
Total Product Revenue, Net
569.61M521.31M336.41M
Total Product Revenue, Net Growth
9.26%54.96%88.07%
License and Other Revenue
--479.00K
License and Other Revenue Growth
---93.61%
Revenue (Other)
-159.88M--
Revenue (Total)
409.73M521.31M336.89M
Revenue (Total) Growth
-21.40%54.74%80.76%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
License and Other Revenue
--479.00K
License and Other Revenue Growth
---93.61%
United States - Product Revenue
442.55M401.55M274.17M
United States - Product Revenue Growth
10.21%46.46%86.89%
Rest of the World - Product Revenue
127.06M119.77M62.24M
Rest of the World - Product Revenue Growth
6.09%92.44%93.43%
Revenue (Other)
-159.88M--
Revenue (Total)
409.73M521.31M336.89M
Revenue (Total) Growth
-21.40%54.74%80.76%